Regeneron Pharmaceuticals, Inc. (LON:0R2M)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 43.75B |
| Revenue (ttm) | 10.37B |
| Net Income (ttm) | 3.25B |
| Shares Out | n/a |
| EPS (ttm) | 28.96 |
| PE Ratio | 13.44 |
| Forward PE | 13.72 |
| Dividend | 1.35 (0.24%) |
| Ex-Dividend Date | May 20, 2025 |
| Volume | 807 |
| Average Volume | 2,852 |
| Open | 550.00 |
| Previous Close | 548.31 |
| Day's Range | 543.21 - 590.35 |
| 52-Week Range | 477.01 - 1,210.92 |
| Beta | n/a |
| RSI | 48.48 |
| Earnings Date | Aug 1, 2025 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]
Financial Performance
In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.
Financial numbers in USD Financial StatementsNews
5 Stocks That Launched New Dividends In This Roller-Coaster Market
Brand new dividends are often the best divvies to buy. Here why.
Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation
TARRYTOWN, N.Y., July 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 13th annual Regeneron Prize for Creative Innovation (the “Regeneron...
ANI Pharma drops as clinical trial for eye implant fails against Regeneron’s Eylea
SA analyst upgrades/downgrades: CVX, TLRY, LULU, REGN
Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025
Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN stock is upgraded to buy.
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
Merck & Co. Inc. (NYSE: MRK) agreed on Wednesday to acquire Verona Pharma plc (NASDAQ: VRNA) for $107 per American Depository Share (ADS) for a total transaction value of approximately $10 billion. ...
Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment
Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma.
Regeneron wins FDA accelerated nod for multiple myeloma therapy
US FDA approves Regeneron's blood cancer therapy
The U.S. Food and Drug Administration has approved Regeneron's cancer therapy, the company said on Wednesday, providing another treatment option for patients with a recurring and common form of blood ...
Regeneron Pharmaceuticals Unusual Options Activity For July 01
Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals . Looking at options history for Regeneron Pharmaceuticals (NASDAQ: REGN) we detected 14 trades...
Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Strong Tailwind
Biotech stock Kiniksa soared after first-quarter results on April 29. Shares are near a buy point of 28.15.
Bayer, Regeneron get EU nod for Eylea's label extension
Bayer's Eylea 8 mg gets EU approval for extended 6-month dosing for macular degeneration & diabetic macular edema. Read more here.
Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025
TARRYTOWN, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2025 financial and operating results on Friday,...
Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade
Regeneron Pharmaceuticals, Inc. faces declining Eylea sales due to competition from Roche's Vabysmo and biosimilars like Amgen's Pavblu, but Dupixent's strong growth and new indications provide a robu...
Regeneron: Negative Scenario Is Being Realized (Rating Downgrade)
Regeneron: Potential Entrant To Weight Loss Market
Nektar Therapeutics Shares Double On Promising Eczema Drug Data
Nektar Therapeutics Inc (NASDAQ: NKTR) stock is surging on Tuesday, with a session volume of 4.7 million compared to an average volume 239.7K as per data from Benzinga Pro . The company released stat...
Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization
Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medications Initiative aims to expand and encourage philanthropy to help patients with retinal ...
Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz
Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.
$100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Regeneron Pharmaceuticals (NASDAQ: REGN) has outperformed the market over the past 20 years by 14.22% on an annualized basis producing an average annual return of 22.54%. Currently, Regeneron Pharmac...
Regeneron, Sanofi win FDA label expansion for Dupixent against rare skin disorder
Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease
The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the elderly and is characterized by itchiness, blisters and lesions.
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal results showing improvements in sustained disease remission and reductions...